244 related articles for article (PubMed ID: 29383624)
21. [Paroxysmal nocturnal hemoglobinuria treated with eculizumab in Wakayama, Japan: a retrospective analysis].
Tamura S; Furuya Y; Hori Y; Hiroi T; Yamashita Y; Oiwa T; Murata S; Mushino T; Nishikawa A; Hanaoka N; Sonoki T
Rinsho Ketsueki; 2020; 61(6):605-611. PubMed ID: 32624532
[TBL] [Abstract][Full Text] [Related]
22. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
DeZern AE; Dorr D; Brodsky RA
Eur J Haematol; 2013 Jan; 90(1):16-24. PubMed ID: 23046169
[TBL] [Abstract][Full Text] [Related]
23. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Muus P; Dührsen U; Risitano AM; Schubert J; Luzzatto L; Schrezenmeier H; Szer J; Brodsky RA; Hill A; Socié G; Bessler M; Rollins SA; Bell L; Rother RP; Young NS
Blood; 2007 Dec; 110(12):4123-8. PubMed ID: 17702897
[TBL] [Abstract][Full Text] [Related]
24. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
25. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
26. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
28. [Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China].
Wang LY; Hu QL; Chen M; Yang C; Han B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):184-189. PubMed ID: 38604796
[No Abstract] [Full Text] [Related]
29. Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan.
Ikezoe T; Noji H; Ueda Y; Kanda Y; Okamoto S; Usuki K; Matsuda T; Akiyama H; Shimono A; Yonemura Y; Kawaguchi T; Chiba S; Kanakura Y; Nishimura JI; Ninomiya H; Obara N
Int J Hematol; 2022 Apr; 115(4):470-480. PubMed ID: 35146630
[TBL] [Abstract][Full Text] [Related]
30. Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.
Groth M; Singer S; Niedeggen C; Petermann-Meyer A; Röth A; Schrezenmeier H; Höchsmann B; Brümmendorf TH; Panse J
Ann Hematol; 2017 Feb; 96(2):171-181. PubMed ID: 27837250
[TBL] [Abstract][Full Text] [Related]
31. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
32. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
33. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients.
Ishiyama K; Nakao S; Usuki K; Yonemura Y; Ikezoe T; Uchiyama M; Mori Y; Fukuda T; Okada M; Fujiwara SI; Noji H; Rottinghaus S; Aguzzi R; Yokosawa J; Nishimura JI; Kanakura Y; Okamoto S
Int J Hematol; 2020 Oct; 112(4):466-476. PubMed ID: 32869125
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Röth A; Araten DJ; Larratt L; Kulasekararaj AG; Maciejewski JP; Wilson A; Gustovic P; Kanakura Y
Eur J Haematol; 2020 Nov; 105(5):561-570. PubMed ID: 32640047
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
36. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
[TBL] [Abstract][Full Text] [Related]
38. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
[TBL] [Abstract][Full Text] [Related]
39. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.
Schwartz CE; Stark RB; Borowiec K; Nolte S; Myren KJ
Orphanet J Rare Dis; 2021 Sep; 16(1):389. PubMed ID: 34526067
[TBL] [Abstract][Full Text] [Related]
40. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
